Tag: population

In this 2025 ingredient transparency update, Emma highlights growing public interest in methane-producing gut bacteria, microbiome imbalance, and non-clinical digestive support. The release explores how plant-based formulations may help support intestinal motility, microbial balance, and daily bowel regularity without relying on probiotics or synthetic cleanses.

NativePath’s Clean-Label Creatine Powder Combines L-Leucine, L-Carnitine, and Creatine Monohydrate for Daily Muscle and Energy Support Without Resistance Training

In this 2025 product transparency update, BloodVitals details how its pulse oximeter supports real-time blood vitals tracking through non-invasive technology designed for seniors and at-home wellness users. The release explores the shift toward pain-free health monitoring, the rising demand for accessible oxygen level tools, and the increasing role of pulse oximeters in managing vital signs outside clinical settings.

- IDE approval obtained; U.S. pilot study clinical site launched at Johns Hopkins
- Series B round in planning to support pivotal U.S. trial
- New CEO appointment signals next phase of growth and expansion

According to Precedence Research, the global web3 gaming market size is calculated at USD 37.55 billion in 2025 and is expected to be worth around USD 182.98 billion by 2034, registering a robust CAGR of 19.24% from 2025 to 2034. North America accounted for USD 11.34 billion in 2024 and is poised to maintain its dominance with a double-digit CAGR of 19.40%.

Press Release

PARIS and CAMBRIDGE, Mass., July 07, 2025 (GLOBE NEWSWIRE) -- NANOBIOTIX (Euronext: NANO –– NASDAQ: NBTX – the ‘‘Company’’),  a late-stage clinical biotechnology company pioneering physics-based approaches to expand treatment possibilities for patients with cancer, today announced two important developments that aim to reinforce the global positioning of potential first-in-class radioenhancer JNJ-1900 (NBTXR3), which is licensed by Janssen Pharmaceutica NV, a Johnson & Johnson company.

SEQUANA MEDICAL ANNOUNCES NEW SHARE CAPITAL AMOUNT

Planned submission of IND application in 2025; Phase 1 clinical trial to follow if IND application approved

-- Patients treated with bezuclastinib showed a superior mean change in total symptom score at 24 weeks (-24.3 points vs. -15.4 points, -8.91 point placebo-adjusted difference; p=0.0002), compared to patients treated with placebo, establishing new benchmarks for placebo-adjusted and absolute symptomatic improvement for this patient population --

-- Bezuclastinib demonstrated a powerful effect on mast cell burden, with 87.4% of patients treated with bezuclastinib achieving at least 50% reduction in serum tryptase compared to 0% of patients treated with placebo --